Medical oncologist Dr. Andrew Zelenetz clarifies the differences between the label of a biosimilar and that of its reference product.
Under the FDA's guidance, the label of a biosimilar and its reference product are essentially the same. Dr. Andrew Zelenetz explores the implications of this. Clear and transparent labels are key in helping to ensure precise prescribing decisions. Visit www.ExamineBiosimilars.com for more info.